NCT01213732View on ClinicalTrials.gov

Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

September 30, 2011

Conditions
Patients With Intransit Stage III/IV Melanoma
Interventions
OTHER

Isolated inferior limb perfusion

Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).

Trial Locations (2)

Unknown

Azienda Ospedaliera Universitaria San Martino, Genova

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Sponsors

Collaborators (1)

InnoPharma Inc.
All Listed Sponsors
collaborator

InnoPharma Inc.

INDUSTRY

collaborator

Eudax S.r.l.

INDUSTRY

lead

Philogen S.p.A.

INDUSTRY

NCT01213732 - Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma | Biotech Hunter | Biotech Hunter